经皮冠状动脉介入术后慢性维持期单用阿司匹林与氯吡格雷的比较(HOST-EXAM):研究者发起的、前瞻性、随机、开放标签、多中心试验
HOST-EXAM在韩国37个中心纳入5530例DES置入后维持双联抗血小板治疗6–18个月无临床事件、年龄≥20岁的患者,排除任何缺血和主要出血并发症者,1:1随机接受氯吡格雷75 mg每日一次或阿司匹林100 mg每日一次单药治疗24个月。主要终点为全因死亡、非致死性心肌梗死、卒中、因急性冠脉综合征再入院及BARC 3型及以上出血的复合终点。氯吡格雷组主要终点发生152例(5.7%),阿司匹林组207例(7.7%)(HR 0.73,95%CI 0.59–0.90;p=0.0035)。作者认为,在DES置入后慢性维持期,氯吡格雷单药较阿司匹林单药显著降低该复合终点风险;对于需要长期抗血小板单药治疗的患者,氯吡格雷单药在预防未来不良临床事件方面优于阿司匹林单药。
要点
- DES置入后6–18个月无事件患者,氯吡格雷75 mg每日一次单药24个月主要终点5.7%(152例) vs 阿司匹林100 mg每日一次7.7%(207例),HR 0.73(95%CI 0.59–0.90),p=0.0035。
- 主要终点为全因死亡、非致死性心肌梗死、卒中、因急性冠脉综合征再入院及BARC 3型及以上出血的复合终点,在意向治疗人群中分析。
- 共筛查5530例,5438例(98.3%)随机分组:氯吡格雷组2710例(49.8%),阿司匹林组2728例(50.2%);主要终点 ascertainment 完成于5338例(98.2%)。
- 作者认为,对于经皮冠状动脉介入术后需要长期抗血小板单药治疗的患者,氯吡格雷单药在预防未来不良临床事件方面优于阿司匹林单药。
适用人群与场景
- 年龄至少20岁、经药物洗脱支架(DES)行经皮冠状动脉介入术后维持双联抗血小板治疗6–18个月且无临床事件的患者。
- 排除任何缺血和主要出血并发症的患者。
- 场景为经皮冠状动脉介入术后慢性维持期门诊随访人群。
处置流程与药物剂量
- 氯吡格雷75 mg每日一次口服,或阿司匹林100 mg每日一次口服,疗程24个月,1:1随机分配。
研究设计与关键结果
- 研究类型:研究者发起的、前瞻性、随机、开放标签、多中心试验,在韩国37个研究点开展。
- 样本量:筛查5530例,随机分组5438例(98.3%):氯吡格雷组2710例(49.8%),阿司匹林组2728例(50.2%);主要终点 ascertainment 完成5338例(98.2%)。
- 主要终点(全因死亡、非致死性心肌梗死、卒中、因急性冠脉综合征再入院及BARC 3型及以上出血的复合终点)24个月随访:氯吡格雷组152例(5.7%) vs 阿司匹林组207例(7.7%),HR 0.73(95%CI 0.59–0.90),p=0.0035。
- 试验注册号:ClinicalTrials.gov NCT02044250。
证据类型、等级与局限
- 证据类型:前瞻性、随机、开放标签、多中心试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在DES置入后慢性维持期,氯吡格雷单药较阿司匹林单药显著降低全因死亡、非致死性心肌梗死、卒中、因急性冠脉综合征再入院及BARC 3型及以上出血的复合终点风险。
- 作者认为,对于经皮冠状动脉介入术后需要长期抗血小板单药治疗的患者,氯吡格雷单药在预防未来不良临床事件方面优于阿司匹林单药。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Optimal antiplatelet monotherapy during the chronic maintenance period in patients who undergo coronary stenting is unknown. We aimed to compare head to head the efficacy and safety of aspirin and clopidogrel monotherapy in this population.
METHODS: We did an investigator-initiated, prospective, randomised, open-label, multicentre trial at 37 study sites in South Korea. We enrolled patients aged at least 20 years who maintained dual antiplatelet therapy without clinical events for 6-18 months after percutaneous coronary intervention with drug-eluting stents (DES). We excluded patients with any ischaemic and major bleeding complications. Patients were randomly assigned (1:1) to receive a monotherapy agent of clopidogrel 75 mg once daily or aspirin 100 mg once daily for 24 months. The primary endpoint was a composite of all-cause death, non-fatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and Bleeding Academic Research Consortium (BARC) bleeding type 3 or greater, in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02044250.
FINDINGS: Between March 26, 2014, and May 29, 2018, we enrolled 5530 patients. 5438 (98·3%) patients were randomly assigned to either the clopidogrel group (2710 [49·8%]) or to the aspirin group (2728 [50·2%]). Ascertainment of the primary endpoint was completed in 5338 (98·2%) patients. During 24-month follow-up, the primary outcome occurred in 152 (5·7%) patients in the clopidogrel group and 207 (7·7%) in the aspirin group (hazard ratio 0·73 [95% CI 0·59-0·90]; p=0·0035).
INTERPRETATION: Clopidogrel monotherapy, compared with aspirin monotherapy during the chronic maintenance period after percutaneous coronary intervention with DES significantly reduced the risk of the composite of all-cause death, non-fatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and BARC bleeding type 3 or greater. In patients requiring indefinite antiplatelet monotherapy after percutaneous coronary intervention, clopidogrel monotherapy was superior to aspirin monotherapy in preventing future adverse clinical events.
FUNDING: ChongKunDang, SamJin, HanMi, DaeWoong, and the South Korea Ministry of Health and Welfare.
参考来源
- Koo BK, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021. PMID: 34010616. doi:10.1016/S0140-6736(21)01063-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。